West Pharmaceutical Services, Inc. · NYSE:WST
West Pharmaceutical Services — CJS "New Ideas" Investor Conference 2010
17 slides from West Pharmaceutical Services's conference presentation, Jan 14, 2010
Slide 1: CJS "New Ideas" Investor Conference
Donald E. Morel, Jr., Ph.D. Chairman and Chief Executive Officer William J. Federici Vice President and Chief Financial Officer Investor Relations Contact: Michael A. Anderson Vice President and Treasurer mike.anderson@westpharma.com CJS “New Ideas” Investor Conference New York, New York January 14,
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on management’s beliefs and assumptions, current expectati
Slide 3: Corporate Profile
Corporate Profile • Founded in 1923 • Leading global supplier of components and systems for injectable drug delivery – Vial closure systems – Prefillable syringe components – Components for diagnostics – Devices and device sub- assemblies Devices – Safety and administration systems • Market capitali
Slide 4: 2009 in Retrospect
2009 in Retrospect • Challenges: – Adverse effects of pension expense, currency effects – Recession impacted customer behavior/order patterns • Tighter cost/ working capital/inventory management and • Major program delays and cancellations – Slowed growth coming into 2009 continued through Q2 • Q3 r
Slide 5: Long Term Business Drivers
Long Term Business Drivers • Demographics • Growth in Biologics & Vaccines • Requirement for easy, safe, accurate dosing • Combination product growth • Generic growth West supplies sophisticated • Increasing global access to packaging systems for the top 20 advanced healthcare biologic drugs (by sal
Slide 6: Therapeutic Category Drivers
Therapeutic Category Drivers Projected Category Key Customers Growth Diabetes 8 - 10% Oncology 6 - 8% Vaccines 4 - 6% Autoimmune 6 - 8% 6
Slide 7: 2010 Outlook
2010 Outlook • Global economic conditions remain soft, but show signs of improvement • Uncertainty over pending US healthcare legislation • Global pharma revenue growth projected to be 4-6% (per IMS) • North America growth projected at 4.5 - 5.5% • Europe growth moderate 2-4% • Emerging economies sh
Slide 8: Business Unit Re-alignment
Business Unit Re-alignment Packaging Systems Delivery Systems (How drugs are contained) (How drugs are administered) Primary Container Solutions Administration Systems • Small volume parenteral • Safety systems (NovaGuard, Eris) packaging • Reconstitution systems - • Large volume parenteral MediMop
Slide 9: Five-Year Growth Opportunity
Five-Year Growth Opportunity Packaging Systems Delivery Systems (How drugs are contained) (How drugs are administered) Primary Container Solutions Administration Systems $1.5 billion market for components with unit $2 billion combined markets for safety, growth 0% to 8% per year, depending on prefil
Slide 10: Our Growth Strategy
Our Growth Strategy Packaging Systems (How drugs are contained) West’s Competitive Advantages: Primary Container Solutions • Unmatched expertise in drug - material interactions • Therapeutic segment focus • Market leader in packaging for • Generate incremental value per biologics unit • Protected IP
Slide 11: Value Proposition
Value Proposition Revenue and Margin Opportunity PROPRIETARY PRODUCTS éris™ Westar® RU NovaGuard™ Westar® RS Mix2Vial® Standard Standard Disposable Disposable Device Device Consumer Consumer Components Components Components Components Products Products 11
Slide 12: Our Growth Strategy
Our Growth Strategy Packaging Systems Delivery Systems (How drugs are contained) (How drugs are administered) Primary Container Solutions Administration Systems • Therapeutic segment focus • Concentrate on systems for unmet • Generate incremental value per market needs unit • Build market share in m
Slide 13: Delivery Systems - Key Programs
Delivery Systems - Key Programs ConfiDose® MixJect® Auto- Daikyo Crystal Zenith® injector NovaGuard™ Safety éris™ Vial2Bag™ Mix2Vial® Needle Device Safety Needle (luer-lock syringe) Devicesyringe) (fixed-needle 13
Slide 14: Management Focus
Management Focus • Packaging Systems Segment – Organic growth (on average) of 3-5% per year – Margin expansion through improved operating efficiency – Positive mix with increasing biologic product sales – Capital investments targeted at quality improvements • Delivery Systems Segment – Deliver the p
Slide 15: Summary
Summary • A valuable franchise Injectable Container Solutions – Substantial market share – Proprietary technology – Diversified Customer Base – Global footprint • Positioned to grow – Strength in new product pipeline Prefillable Syringe Systems – Preferred products for biologics Safety and • With th
Slide 16: Donald E. Morel, Jr., Ph.D. and William J. Federici
Donald E. Morel, Jr., Ph.D. Chairman and Chief Executive Officer William J. Federici Vice President and Chief Financial Officer Investor Relations Contact: Michael A. Anderson Vice President and Treasurer mike.anderson@westpharma.com CJS “New Ideas” Investor Conference New York, New York January 14,
Slide 17: Slide 17
West Pharmaceutical Services — CJS "New Ideas" Investor Conference 2010 on 6ix